Innoviva, Inc. balance sheet INVA

Annual Quarterly

As of Sep 30, 2026, Innoviva, Inc. had total assets of $1.5 billion. Total assets were up 7.6% from a year earlier. Stockholders' equity was $1.1 billion. It held $986.2 million in cash and investments against $269.9 million of total debt, net cash of $716.4 million. The current ratio, current assets divided by current liabilities, was 15.44.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	581 +22.0%	570 +43.5%	603 +89.0%	551 +80.7%	477 +82.8%	398 +83.2%	319 +78.9%	305 +57.6%
Long-term investments	405 +17.8%	441 +48.4%	413 +41.9%	404 +18.4%	344 -20.8%	297 -33.1%	291 -38.9%	342 -23.1%
Cash and investments	986 +20.2%	1,012 +45.6%	1,016 +66.5%	955 +47.8%	820 +18.1%	695 +5.0%	610 -6.8%	647 +1.4%
Inventory	43 +11.7%	39 -20.5%	39 -6.4%	39 +16.2%	38 +12.1%	49 +33.6%	41 +10.8%	34 -17.2%
Total current assets	772 +12.8%	753 +15.6%	773 +32.7%	728 +31.2%	685 +70.9%	652 +81.9%	582 +86.9%	554 +61.0%
Property and equipment, net	2 +33.3%	2 +372.9%	2 +343.5%	2 +202.5%	2 +181.1%	0 +5.6%	0 +49.1%	1 +6.4%
Goodwill	18 +0.0%	18 +0.0%	18 +0.0%	18 +0.0%	18 +0.0%	18 +0.0%	18 +0.0%	18 +0.0%
Total assets	1,538 +7.6%	1,703 +27.7%	1,837 +46.4%	1,635 +25.7%	1,429 +16.0%	1,334 +8.9%	1,254 -1.0%	1,301 +4.6%
Liabilities and equity
Accounts payable	6 +4.1%	4 -25.4%	7 +38.7%	5 +132.9%	6 +49.7%	5 +164.0%	5 +428.1%	2 -68.3%
Total current liabilities	50 +3.2%	47 -80.9%	37 -84.4%	50 -78.9%	48 -78.3%	247 +774.2%	235 +685.7%	236 +519.1%
Stockholders' equity	1,138	1,233	1,342	1,173	—	—	—	—
Debt
Debt due within a year	—	—	—	—	—	192	192	192
Long-term debt	259 +0.6%	258 +0.6%	258 +0.6%	258 +0.6%	257 +0.5%	257 -42.5%	257 -42.5%	256 -42.6%
Lease liabilities	11 +597.1%	11 +465.0%	11 +377.9%	11 +310.3%	2 -48.8%	2 -42.3%	2 -7.8%	3 -3.2%
Total debt	270 +4.2%	270 -40.2%	269 -40.3%	269 -40.4%	259 -42.6%	451 +0.0%	451 +0.4%	451 +0.4%
Net cash	716 +27.6%	742 +204.2%	747 +369.8%	686 +251.1%	561 +130.2%	244 +15.6%	159 -22.7%	196 +3.5%
Ratios
Current ratio	15.44x	16.01x	21.13x	14.64x	14.12x	2.64x	2.48x	2.35x
Debt to equity	0.24x	0.22x	0.20x	0.23x	—	—	—	—
Return on equity	17.01%	28.97%	37.59%	23.12%	—	—	—	—
Return on assets	12.58%	20.98%	27.46%	16.58%	8.91%	2.90%	-4.76%	1.80%
Book value per share	15.90	16.98	18.18	15.71	—	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: INVA (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Burlingame, CA
SEC filer status: Large accelerated filer
SEC CIK: 1080014
Former names: THERAVANCE INC (until Dec 7, 2015); ADVANCED MEDICINE INC (until Aug 2, 2000)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.